Aplagon raised €4.8M in a funding round led by Fåhraeus Startup and Growth AB and the EIC Fund to support its Phase 2 clinical programme in end-stage kidney disease.
Amount Raised
€4.8 Million
Round Type
Funding Round
HelsinkiBiotechnologyHealth CareTherapeuticsInvestors
Description
Aplagon, based in Helsinki, is a clinical-stage biotechnology company focused on developing an antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The funding round, amounting to €4.8M, will aid the company's expansion into a new Phase 2 clinical programme. Key investors included the European Innovation Council Fund and Finnish foundations. Aplagon aims to target thrombo-inflammatory diseases with its innovative therapeutic platform.
Quick answer
Aplagon raised €4.8 Million in a Funding Round round, dated June 17, 2026. Investors: European Innovation Council Fund, Jenny And Antti Wihuri Foundation, Innovestor, Gösta Serlachius Fine Arts Foundation and Fåhraeus Startup And Growth AB. Aplagon is based in Helsinki, Uusimaa, Finland.
- How much did Aplagon raise?
- Aplagon raised €4.8 Million in a Funding Round round on June 17, 2026.
- Who invested in Aplagon?
- European Innovation Council Fund, Jenny And Antti Wihuri Foundation, Innovestor, Gösta Serlachius Fine Arts Foundation and Fåhraeus Startup And Growth AB are named as investors in this round.
- What does Aplagon do?
- Aplagon is a biotechnology company focused on developing innovative therapies targeting thrombo-inflammatory diseases.
- Where is Aplagon based and how big is it?
- Aplagon is based in Helsinki, Uusimaa, Finland. Fundz records about 6 employees.
- Who are the decision-makers at Aplagon?
- Fundz holds 1 contact at Aplagon, including the Clinical Study Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Aplagon that raised within 45 days of this round, from Fundz verified event records.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
- Hyku Biosciences raised $8.6M on July 30, 2026.
- HCW Biologics raised $1.5M (Post-IPO Equity) on July 29, 2026.
- Adjuvia Therapeutics raised $8M (Seed) on July 29, 2026.
- CORE Biomedicine raised $21M (Series A) on July 28, 2026.
- Torrey Pines Medicine raised an undisclosed amount (Angel) on July 28, 2026.
Who to call at Aplagon, and when
A new round usually means Aplagon is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aplagon raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aplagon, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aplagon. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aplagon raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Aplagon raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.